|

Stocks remain at the mercy of Omicron uncertainty

News flow-sensitive: It was a strong day for European equity markets on Wednesday – the FTSE 100 rose almost 1.6% for its best day in four months, while the DAX rallied 2.5%, its strongest session in eight months. Bourses across the continent rallied firmly as markets paid back much of the faster-taper/stickier-inflation narrative from Tuesday: getting a grip on inflation is no bad thing. Also, the market seemed to be buying more into the idea that we shouldn’t panic over omicron.  

Or is it? European markets declined ~1% in early trade Thursday, taking their cue from a soft session on Wall Street. US markets tried to bounce, rising firmly at the open, but ended sharply lower as California confirmed the first omicron case in the US. Panic? Not quite but certainly concern and uncertainty produced a pretty wild session of swings. The S&P 500 traded through its 50-day moving average where there is supposed to be lots of support around 4,530, closing at 4,513, having traded as high as 4,652. Quite how the market would move so swiftly when it’s a certainty that omicron is everywhere is unclear, but shows the acute sensitivity equity markets have to the Covid news flow – more like 2020 than 2021 in some ways.  

Or is it? Australia’s health chief is the latest to say there is no evidence omicron is any deadlier. “Of the over 300 cases that have now been diagnosed in many countries, they have all been very mild or in fact had no symptoms at all,” the chief medical officer, Paul Kelly, said. Hardly a reason to panic – but markets are responding not to the virus itself but Monetary policy is heading in the opposite direction to accommodate, ammo well and truly spent, and the fiscal response is not as straightforward as it was in 2020. Just as well it’s not going to have the same economic impact as before...fingers crossed. GSK shares inched up as it said its Covid antibody treatment is still effective against the new variant. Meanwhile, against all this we have talk of Russian troop build-ups near its Ukraine border and Nato suggesting we should prepare for the worst. 

We had more from Jay Powell in his second day of testimony on capitol hill. There was lots more about speeding the pace of tapering, on inflation, about the retirement of the phrase ‘transitory’ and what they meant by that term the first place. But the best for me was: ‘We are not at all sure of inflation forecast’. No, really? You’ve nailed it thus far...I have every confidence.  

Before the CDC confirmed the omicron case the market liked a cooling in inflation component of the latest ISM Manufacturing PMI, which overall still showed strong expansion. The prices paid index declined to 82.4 versus 85.7 in October. New orders and employment both rose. A business roundtable index showed overall confidence at a 20-year high – though naturally, this was just before the omicron variant emerged to unsettle markets. 

As an aside, lots of rotation has been a hallmark of 2021 – most stocks have had a drawdown of 10% or more at some point this year. Just the indices haven’t reflected this because there has been so much internalization of the buying and selling and this incremental grind higher for various reasons: FOMO, TINA, whatever you call it. Pullbacks or even shakeouts can be useful for the market not only to allow new entrants but also to reset expectations. We’ve now had 2/3 good shakeouts – trapped supply above will prove resistance, but this might be a useful reset ahead of Christmas. 

In short the market remains acutely sensitive to anything about omicron and will respond on pos/neg headlines with abandon, which makes positioning difficult – a market that will cut both bulls and bears. Sector-wise, healthcare and consumer defensives won out yesterday, quality tech provided some resistance with Apple and Microsoft barely declining. Momentum was a problem with ARKK down almost 7%, almost 40% below the all-time high struck earlier this year. This is mirrored today on the FTSE with the likes of Unilever and United Utilities among the few risers. Shell and BP also higher as crude rallied 1% though oil remains under a heap of pressure with OPEC+ set to meet today to decide on whether to increase output by 400k bpd in January. A pause in the loosening of output controls would help sentiment in the market and is increasingly expected.  

WTI (Jan) found new resistance at the new 23.6% retracement area, not indicative of many bids coming in yet. Speculative positioning will remain weak until this clears out.

Oil

Author

Neil Wilson

Neil Wilson

Markets.com

Neil is the chief market analyst for Markets.com, covering a broad range of topics across FX, equities and commodities. He joined in 2018 after two years working as senior market analyst for ETX Capital.

More from Neil Wilson
Share:

Editor's Picks

EUR/USD struggles to hold above 1.1800 ahead of US data

EUR/USD finds it difficult to gather recovery momentum and retreats below 1.1800 in the second half of the day on Thursday. The US Dollar (USD) stays resilient against its peers after the hawkish surprise in FOMC Minutes, weighing on the pair ahead of the next batch of US data.

GBP/USD recovers above 1.3500 amid better mood

GBP/USD finds fresh demand and rises back above 1.3500 in the European session on Thursday. Improving risk sentiment and renewed US Dollar weakness are helping the pair recover ground ahead of mid-tier US data releases and Fedspeak. 

Gold retreats from daily highs, trades below $5,000

Gold finds it difficult to stabilize above the $5,000 psychological mark on Thursday and trades slightly below this level in the early American session. Escalating geopolitical tensions in the Middle East help XAU/USD hold its ground, while the broad-based USD strength caps the pair's upside.

Injective token surges over 13% following the approval of the mainnet upgrade proposal

Injective price rallies over 13% on Thursday after the network confirmed the approval of its IIP-619 proposal. The green light for the mainnet upgrade has boosted traders’ sentiment, as the upgrade aims to scale Injective’s real-time Ethereum Virtual Machine architecture and enhance its capabilities to support next-generation payments. The technical outlook suggests further gains if INJ breaks above key resistance.

Hawkish Fed minutes and a market finding its footing

It was green across the board for US Stock market indexes at the close on Wednesday, with most S&P 500 names ending higher, adding 38 points (0.6%) to 6,881 overall. At the GICS sector level, energy led gains, followed by technology and consumer discretionary, while utilities and real estate posted the largest losses.

Injective token surges over 13% following the approval of the mainnet upgrade proposal

Injective price rallies over 13% on Thursday after the network confirmed the approval of its IIP-619 proposal. The green light for the mainnet upgrade has boosted traders’ sentiment, as the upgrade aims to scale Injective’s real-time Ethereum Virtual Machine architecture and enhance its capabilities to support next-generation payments.